Comparison of oncogene mutation detection and telomerase activity for the molecular staging of non-small cell lung cancer

Steven A. Ahrendt, Stephen C Yang, Li Wu, William H. Westra, Jin Jen, Joseph A. Califano, David Sidransky

Research output: Contribution to journalArticle

Abstract

Novel oncogene mutation detection techniques have demonstrated that standard histopathological examination may fail to detect clinically significant metastatic cancer cells. Recently, telomerase activity has been detected in most immortal cell lines and human tumors, potentially providing a novel diagnostic marker. We compared standard histopathological examination with the telomeric repeat amplification protocol assay and either a p53 plaque hybridization or a K-ras mutation ligation assay in the lymph nodes of 12 patents with surgically resectable non-small cell lung cancer. Telomerase activity was detected in 10 of 10 (100%) evaluable tumors. Eight of 9 (89%) histopathologically positive lymph nodes were telomerase positive, and 26 of 48 (54%) histopathologically negative lymph nodes were telomerase positive. In comparison, oligonucleotide plaque hybridization detected metastases in all 3 histopathologically positive nodes and in 3 of 27 histopathologically negative nodes. Similarly, the K-ras mutation ligation assay detected metastases in all 6 histopathologically positive lymph nodes examined and in 1 of 21 histopathologically negative lymph nodes. Thus, most of the 'positive' nodes by telomerase assay did not harbor occult neoplastic cells that shared the same genetic alteration as the primary tumor. The high rate of false positives associated with the telomeric repeat amplification protocol assay limits its role in staging lymph nodes in patients with non- small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)1207-1214
Number of pages8
JournalClinical Cancer Research
Volume3
Issue number7
StatePublished - Jul 1997

Fingerprint

Telomerase
Oncogenes
Non-Small Cell Lung Carcinoma
Lymph Nodes
Mutation
Ligation
Neoplasm Metastasis
Neoplasms
Patents
Tumor Cell Line
Oligonucleotides

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Comparison of oncogene mutation detection and telomerase activity for the molecular staging of non-small cell lung cancer. / Ahrendt, Steven A.; Yang, Stephen C; Wu, Li; Westra, William H.; Jen, Jin; Califano, Joseph A.; Sidransky, David.

In: Clinical Cancer Research, Vol. 3, No. 7, 07.1997, p. 1207-1214.

Research output: Contribution to journalArticle

Ahrendt, Steven A. ; Yang, Stephen C ; Wu, Li ; Westra, William H. ; Jen, Jin ; Califano, Joseph A. ; Sidransky, David. / Comparison of oncogene mutation detection and telomerase activity for the molecular staging of non-small cell lung cancer. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 7. pp. 1207-1214.
@article{79ae37b08dbe4dcabfdf3f64a41aca6a,
title = "Comparison of oncogene mutation detection and telomerase activity for the molecular staging of non-small cell lung cancer",
abstract = "Novel oncogene mutation detection techniques have demonstrated that standard histopathological examination may fail to detect clinically significant metastatic cancer cells. Recently, telomerase activity has been detected in most immortal cell lines and human tumors, potentially providing a novel diagnostic marker. We compared standard histopathological examination with the telomeric repeat amplification protocol assay and either a p53 plaque hybridization or a K-ras mutation ligation assay in the lymph nodes of 12 patents with surgically resectable non-small cell lung cancer. Telomerase activity was detected in 10 of 10 (100{\%}) evaluable tumors. Eight of 9 (89{\%}) histopathologically positive lymph nodes were telomerase positive, and 26 of 48 (54{\%}) histopathologically negative lymph nodes were telomerase positive. In comparison, oligonucleotide plaque hybridization detected metastases in all 3 histopathologically positive nodes and in 3 of 27 histopathologically negative nodes. Similarly, the K-ras mutation ligation assay detected metastases in all 6 histopathologically positive lymph nodes examined and in 1 of 21 histopathologically negative lymph nodes. Thus, most of the 'positive' nodes by telomerase assay did not harbor occult neoplastic cells that shared the same genetic alteration as the primary tumor. The high rate of false positives associated with the telomeric repeat amplification protocol assay limits its role in staging lymph nodes in patients with non- small cell lung cancer.",
author = "Ahrendt, {Steven A.} and Yang, {Stephen C} and Li Wu and Westra, {William H.} and Jin Jen and Califano, {Joseph A.} and David Sidransky",
year = "1997",
month = "7",
language = "English (US)",
volume = "3",
pages = "1207--1214",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Comparison of oncogene mutation detection and telomerase activity for the molecular staging of non-small cell lung cancer

AU - Ahrendt, Steven A.

AU - Yang, Stephen C

AU - Wu, Li

AU - Westra, William H.

AU - Jen, Jin

AU - Califano, Joseph A.

AU - Sidransky, David

PY - 1997/7

Y1 - 1997/7

N2 - Novel oncogene mutation detection techniques have demonstrated that standard histopathological examination may fail to detect clinically significant metastatic cancer cells. Recently, telomerase activity has been detected in most immortal cell lines and human tumors, potentially providing a novel diagnostic marker. We compared standard histopathological examination with the telomeric repeat amplification protocol assay and either a p53 plaque hybridization or a K-ras mutation ligation assay in the lymph nodes of 12 patents with surgically resectable non-small cell lung cancer. Telomerase activity was detected in 10 of 10 (100%) evaluable tumors. Eight of 9 (89%) histopathologically positive lymph nodes were telomerase positive, and 26 of 48 (54%) histopathologically negative lymph nodes were telomerase positive. In comparison, oligonucleotide plaque hybridization detected metastases in all 3 histopathologically positive nodes and in 3 of 27 histopathologically negative nodes. Similarly, the K-ras mutation ligation assay detected metastases in all 6 histopathologically positive lymph nodes examined and in 1 of 21 histopathologically negative lymph nodes. Thus, most of the 'positive' nodes by telomerase assay did not harbor occult neoplastic cells that shared the same genetic alteration as the primary tumor. The high rate of false positives associated with the telomeric repeat amplification protocol assay limits its role in staging lymph nodes in patients with non- small cell lung cancer.

AB - Novel oncogene mutation detection techniques have demonstrated that standard histopathological examination may fail to detect clinically significant metastatic cancer cells. Recently, telomerase activity has been detected in most immortal cell lines and human tumors, potentially providing a novel diagnostic marker. We compared standard histopathological examination with the telomeric repeat amplification protocol assay and either a p53 plaque hybridization or a K-ras mutation ligation assay in the lymph nodes of 12 patents with surgically resectable non-small cell lung cancer. Telomerase activity was detected in 10 of 10 (100%) evaluable tumors. Eight of 9 (89%) histopathologically positive lymph nodes were telomerase positive, and 26 of 48 (54%) histopathologically negative lymph nodes were telomerase positive. In comparison, oligonucleotide plaque hybridization detected metastases in all 3 histopathologically positive nodes and in 3 of 27 histopathologically negative nodes. Similarly, the K-ras mutation ligation assay detected metastases in all 6 histopathologically positive lymph nodes examined and in 1 of 21 histopathologically negative lymph nodes. Thus, most of the 'positive' nodes by telomerase assay did not harbor occult neoplastic cells that shared the same genetic alteration as the primary tumor. The high rate of false positives associated with the telomeric repeat amplification protocol assay limits its role in staging lymph nodes in patients with non- small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0030822710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030822710&partnerID=8YFLogxK

M3 - Article

C2 - 9815801

AN - SCOPUS:0030822710

VL - 3

SP - 1207

EP - 1214

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -